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Disruption to axonal transport is an early pathological feature in Alzheimer’s disease. The amyloid precursor pro-
tein (APP) is a key axonal transport cargo in Alzheimer’s disease since perturbation of its transport increases APP
processing and production of amyloid-b peptide (Ab) that is deposited in the brains of Alzheimer’s disease
patients.APP is transportedanterogradely through axonsonkinesin-1motors.One favouredroute for attachment
ofAPPtokinesin-1 involvesthescaffoldingproteinc-JunN-terminalkinase-interactingprotein-1 (JIP1),whichhas
been shown to bind both APP and kinesin-1 light chain (KLC). However, direct experimental evidence to support a
role of JIP1 in APP transport is lacking. Notably, the effect of loss of JIP1 on movement of APP through axons of
living neurons, and the impact of such loss on APP processing and Ab production has not been reported. To ad-
dress these issues, we monitored how siRNA mediated loss of JIP1 influenced transport of enhanced green fluor-
escent protein (EGFP)-tagged APP through axons and production of endogenous Ab in living neurons.
Surprisingly, we found that knockdown of JIP1 did not affect either APP transport or Abproduction. These results
have important implications for our understanding of APP trafficking in Alzheimer’s disease.
INTRODUCTION
The correct transport of protein and organelle cargoes through
axons (axonal transport) is anessential requirement forproper func-
tioning of neurons. Sincemost proteins are synthesized in neuronal
cellbodies,axonalandsynapticcargoesneed tobe transportedante-
rogradely through axons to their final destinations, whereas trophic
factors and other cargoes are transported retrogradely from the
synapse to the cell body. Indeed, perturbation of axonal transport
is now known to contribute to the pathogenic process in some neu-
rodegenerative diseases (see for reviews (1–4)).
Alzheimer’s disease is the most common form of dementia,
but the molecular mechanisms that cause disease are not fully
understood. However, altered metabolism of amyloid precursor
protein (APP) leading to changes in production of amyloid-b
peptide (Ab) is believed to be central to the disease process.
Ab is an approximately 40–42 amino acid peptide that is
derived fromAPP by proteolytic processing andwhich is depos-
ited in the brains of Alzheimer’s disease patients within amyloid
plaques. Generation of Ab involves processing by b-site APP
cleaving enzyme-1 (BACE1) and g-secretase that cleave APP
at theN- andC-termini, respectively, of theAb sequence. In add-
ition, APP is processed by a- and g-secretase but since
a-secretase cleaveswithin theAb sequence, this route precludes
Ab production (see for review (5)). A large body of evidence
suggests that at least some forms of Ab have pathogenic proper-
ties (see for reviews (6,7)). As such, understanding the mechan-
isms that control APP processing and Ab production has major
relevance to Alzheimer’s disease research.
One route for altering APP processing involves changes to its
transport through axons. Thus, experimental disruption of an-
terograde axonal transport of APP increases production of Ab
†These two authors contributed equally to this study.
‡Present Address: MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0QH UK.
§Present Address: AstraZeneca Neuroscience iMED, MedImmune Limited, Aaron Klug Building, Granta Park, Cambridge, CB21 6GH UK.
}Present Address: MS Society. 372 Edgware Road, London NW2 6ND UK.
∗To whom correspondence should be addressed at: Department of Neuroscience P037, Institute of Psychiatry, De Crespigny Park, Denmark Hill. London
SE5 8AF. UK. Tel: +44 207 8480393; Email: chris.miller@kcl.ac.uk
# The Author 2013. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Human Molecular Genetics, 2013, Vol. 22, No. 22 4646–4652
doi:10.1093/hmg/ddt313







g/article-abstract/22/22/4646/582809 by King's C
ollege Institute of Psychiatry user on 04 April 2019
(8–10). Moreover, since Ab itself disrupts axonal transport
(11–17), one suggestion is that damage to axonal transport pro-
motes a toxic cycle of events. In this scenario, disruption to APP
transport increases Ab production which, in turn, induces more
damage to axonal transport to further elevate Ab production (8).
As such, APP represents a key axonal transport cargo in Alzhei-
mer’s disease.
APP is transported anterogradely through axons on kinesin-1
molecular motors (8,18–20).Most functional kinesin-1 is a het-
erotetramer of two kinesin-1 motor proteins and two kinesin-1
light chains (KLCs). Kinesin-1 contains the motor domain,
whereas the KLC is mainly involved in binding of cargoes
(21). KLC is required for APP transport (8,22), but the mechan-
ism by which APP attaches to KLC is not clear.
In one model, the intracellular C-terminus of APP binds dir-
ectly to KLC to facilitate transport, but some studies have
queried this finding (23,24). Recently, calsyntenin-1 (also
known as alcadein-a) has been shown to be involved in APP
transport (9,25). Calsyntenin-1 is a type-1 membrane-spanning
protein that binds directly to KLC via its intracellular C-
terminus, so as to mediate post-Golgi transport of a subset of
vesicles through axons (26–30). In thismodel,APP does not dir-
ectly attach to KLC or kinesin-1motors but rather is loaded onto
calsyntenin-1 containing vesicle carriers for transport (9,10,25).
Finally, APP may attach to KLC via intermediary scaffolding
proteins such as c-Jun N-terminal kinase-interacting protein-1
(JIP1) or PAT1 (27,31–36). JIP1 is the favoured scaffold since
it binds to both APP and KLC in biochemical assays and a pro-
portion of APP and JIP1 colocalize in axons (27,32,36–41).
Moreover, axonal transport of APP involving JIP1 has been
implicated in APP processing and Ab production (27,41).
However, much of the data supporting a role of JIP1 in axonal
transport and processing of APP involve analyses of fixed cells
or cell lines overexpressing JIP1 and/or APP (27,32,35,36).
Notably, the effect of loss of JIP1 on axonal transport of APP
in living neurons andhowsuch loss affects productionof endogen-
ous Ab have not been reported. Clearly, a proper analysis of the
role of JIP1 in APP transport requires dynamic studies of APP
movement. Here, we address these issues by analyses of neurons
in which JIP1 expression is downregulated with siRNAs.
RESULTS
siRNA loss of JIP1 does not influence Ab production, APP
processing at the a- or b-secretase sites or phosphorylation
of APP at threonine-668
We first tested the role of JIP1 in the production of endogenous
Ab in rat cortical neurons. Todo so,we utilized siRNAs to knock
down JIP1. In the neurons, JIP1 migrated as two major species
which is consistent with previous reports and is probably the
result of differential phosphorylation since JIP1 is a known
phosphoprotein (42,43). Two different siRNAs and a mixture of
both siRNAs all reduced JIP1 to undetectable levels (Fig. 1A).
However, Ab ELISAs revealed that this reduction in JIP1 did not
affect secretion of either Ab(1–40) or Ab(1–42) into the
media (Fig. 1B and C). For comparison and as controls, we
also treated the neurons with siRNAs for calsyntenin-1 and
with the g-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-1-
alanyl]-S-phenylglycine-t-butyl ester (DAPT). Loss of
calsyntenin-1 has been shown to disrupt axonal transport of
APPto increaseAbproduction,whereasDAPTinhibitsg-secretase
cleavageofAPPtodecreaseAbproduction(9,10,44). Inagreement
with these findings, siRNA knockdown of calsyntenin-1 using a
pool of siRNAs previously shown to reduce calsyntenin-1 to
levels ,5% of that seen in control neurons (9) increased
whereas DAPT decreased production of Ab(1–40) and Ab(1–42)
(Fig. 1B and C).
We next enquired whether siRNA knockdown of JIP1 influ-
enced APP expression or its phosphorylation on threonine-668.
JIP1 has been reported to preferentially bind to APP phosphory-
lated on threonine-668 (32). Since the two individual andmix of
both JIP1 siRNAs all reduced JIP1 levels to the same extent
(Fig. 1A), we utilized the siRNA mix for these experiments.
siRNA loss of JIP1 did not alter total APP levels or the levels of
APP phosphorylated on threonine-668 in the neurons (Fig. 2A).
We also enquiredwhether siRNA loss of JIP1 influencedAPP
processing at the a-secretase and BACE1 sites. Processing of
APP by a-secretase and BACE1 generates N-terminal secreted
APP fragments (sAPPa and sAPPb), which can be detected in
conditioned media from cells using antibodies that specifically
recognize each sAPP fragment. Immunoblotting of conditioned
media from control or JIP1 siRNA knockdown neurons with
antibody 22C11 (that detects total sAPP) and antibodies that
detect sAPPa and sAPPb revealed that loss of JIP1 did not influ-
ence the levels of total sAPP, sAPPa or sAPPb (Fig. 2A). These
Figure 1. siRNA knockdown of JIP1 does not affect the production of Ab.
(A) siRNA knockdown of JIP1 in rat cortical neurons. Neurons were treated
with control (Ctrl) siRNA or with two different JIP1 (JIP1#15 and JIP1#16) or
a mixture of both JIP1 siRNAs (JIP1mix). Samples were then probed on immu-
noblots for JIP1 or actin as a loading control.Molecularmassmarkers are shown.
(B) ELISAs showing relative Ab(1–40) and Ab(1–42) levels (expressed as a
percentage of control values) in conditioned media from neurons treated with
control siRNA, JIP1#15, JIP1#16, JIP1mix or calsyntenin-1 siRNAs. Also
shown are neurons treated with DAPT. Statistical significance was determined
by one-way ANOVA with a Bonferroni post hoc test. N ¼ 6 error bars are
SEM; ∗∗∗P , 0.001.
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findings are consistent with the Ab assays, which also suggest
that JIP1 knockdown does not affect APP processing.
Finally, we enquired whether loss of JIP1 influenced
calsyntenin-1 levels in the neurons since APP is transported
through axons by kinesin-1 on calsyntenin-1 carriers and loss
of calsyntenin-1 affects APP processing (9,10,25). However,
loss of JIP1 had no discernible effect on calsyntenin-1 levels
(Fig. 2A). Thus, loss of JIP1 in neurons does not influence en-
dogenous APP levels, phosphorylation of endogenous APP at
threonine-668, processing of endogenousAPP at thea-secretase
or BACE1 sites or production of endogenous Ab.
Since loss of calsyntenin-1 affects APP processing, Ab pro-
duction and axonal transport of APP (9,10,25) (and see
Fig. 1), we also monitored JIP1 levels in neurons treated with
calsyntenin-1 siRNAs. However, we detected no difference in
JIP1 levels between control and calsyntenin-1 siRNA knock-
down neurons (Fig. 2B).
siRNA loss of JIP1 does not noticeably influence axonal
transport of APP
To examine the role of JIP1 in the axonal transport of APP, we
quantified movement of enhanced green fluorescent protein
(EGFP)-tagged APP (APP-EGFP) through axons of transfected
living rat cortical neurons following siRNA knockdown of JIP1
using time-lapse microscopy. To avoid any possible artifacts
produced by high levels of APP-EGFP expression, we chose
for study, cells expressing low levels of APP-EGFP as judged
by brightness of the EGFP signal. This approach is line with
our previous studies (9,29,45). Kymographs were generated
from the time-lapse movies, and these were used to calculate
the velocities and flux rates of APP-EGFPmovement in both an-
terograde and retrograde directions. Flux rates were determined
by counting the numbers of APP-EGFP particles that crossed a
defined line within the mid-section of axons as previously
described by us and others (8,9,46). In control siRNA treated
neurons,APP-EGFPmoved throughaxons inapredominantlyan-
terograde direction at fast speeds of between1–9 mm/s and 1–
5 mm/s in the anterograde and retrograde directions, respectively.
These velocities and the bias towards anterograde movement
are similar to those described previously formovement of fluores-
cent protein-tagged APP in neurons (8,9,18,19,46–48). siRNA
knockdown of JIP1 did not significantly alter the velocities of
APP-EGFP movement in either anterograde or retrograde direc-
tions, the bias towards anterograde movement, or the flux rates
of anterograde or retrogrademovements (Fig. 3) (and see Supple-
mentary data). Thus, loss of JIP1 has no noticeable effect on
axonal transport of APP through axons of living rat cortical
neurons.
The levels of JIP1 are not altered in Alzheimer’s disease
brains
To begin to determine whether JIP1 is altered in Alzheimer’s
disease, we monitored the levels of JIP1 protein in control and
Braak stage V-VI Alzheimer’s cortical brain samples (see
Table1, for details of patient samples). The age at death andpost-
mortemdelaywas not significantly different between the control
andAlzheimer’s disease samples. However, we found no differ-
ences in the levels of JIP1 between the two sample sets (Fig. 4).
DISCUSSION
APP is transported anterogradely through axons by kinesin-1
motors (8,18–20), but the mechanisms that mediate attachment
of APP to kinesin-1 are not properly understood. JIP1 is a ligand
for KLC and via its PTB domain also binds to the C-terminus of
APP (27,32,36–41). As such, JIP1 has been favoured as a scaf-
fold to connect APP to KLC/kinesin-1 for anterograde axonal
transport (27,32,35,36). Here, we directly tested the role of
JIP1 in axonal transport of APP by quantifying APP-EGFP
movement in JIP1 siRNA knockdown neurons. Despite highly
efficient knockdown of JIP1, we detected no changes in APP
movement in either anterograde or retrograde directions follow-
ing loss of JIP1.
Disruption to axonal transport of APP influences its process-
ing and production of Ab (8–10). Others have shown that over-
expression of JIP1 decreases Ab production but these studies
were conducted in non-neuronal or neuroblastoma cells overex-
pressing APP (27,41). Our analyses revealed no effect of loss of
JIP1 on endogenous Ab production in bona fide neurons, and
these findings are consistent with the absence of an effect of
JIP1 loss on axonal transport of APP in the same neurons. Of
course, it is possible that JIP1 facilitates axonal transport of a
proportion of APP on kinesin-1 motors but that in the JIP1
siRNA knockdown neurons, this effect is not noticeable due to
switching of APP transport to other kinesin-1 carriers, such as
those containing calsyntenin-1 so as to rescue any phenotype.
Calsyntenin-1 has recently been shown to mediate transport of
Figure 2. (A) siRNA knockdown of JIP1 does not affect APP processing or
calsyntenin-1 levels in rat cortical neurons. Neurons were treated with control
(Ctrl) or JIP1mix siRNAs(JIP1) and the samplesprobedon immunoblots for full-
length APP (APP), APP phosphorylated on threonine-668 (pAPP), total sAPP,
sAPPa and sAPPb in conditioned media, and calsyntenin-1 (Cstn); actin is
shown as a loading control. No significant changes in the levels of any of these
proteins or phosphorylation of APP on threonine-668 were detected between
control or JIP1-siRNA treated neurons (Student’s t-test n ¼ 3). (B) siRNA
knockdown of calsyntenin-1 does not affect JIP1 protein levels. Neurons were
treated with control (Ctrl) or calsyntenin-1 (Cstn) siRNAs and the samples
probed on immunoblots for JIP1 and actin as a loading control. No significant
changes in the levels of JIP1 were detected between control or calsyntenin-1
siRNA-treated neurons (Student’s t-test n ¼ 3).
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APPby kinesin-1 (9,10). Thus,while our results cannot formally
eliminate any role of JIP1 in kinesin-1 transport of APP, the
absence of any noticeable effect of loss of JIP1 on APP move-
ment, APP processing or Ab production together argue against
amajor role for JIP1 in axonal transport ofAPP at least in the cor-
tical neurons utilized here.
In contrast to an absence of effect of JIP1, siRNA loss of
calsyntenin-1 reduces axonal transport of APP to increase Ab pro-
duction(9,10)(andseeFig.1).Calsyntenin-1 isa type-1membrane-
spanning protein that attaches via its intracellular C-terminus to
KLC (26–28). Calsyntenin-1 also binds to the adaptor protein
X11b (also known as X11-like and munc-18-interacting
protein-2) (49). There is evidence that X11b functions as a
coat protein to direct loading of cargoes into particular vesicle
sub-types (50). X11b also binds to the C-terminus of APP
(51,52) and like calsyntenin-1, modulating X11b expression
affects APP processing and Ab production (53–55). Thus,
X11b may load APP onto calsyntenin-1 containing vesicles
for post Golgi transport by kinesin-1 through axons and disrup-
tion to this transport either via loss of calsyntenin-1 orX11bmay
promote amyloidogenic processing of APP. JIP1 has been
reported to be mislocalised in Alzheimer’s disease (56) but we
detected no changes in the total levels of JIP1 in Alzheimer’s
disease brains. This contrasts with calsyntenin-1 where both
decreased protein levels and altered processing have been
reported (9,57,58). Thus, defective axonal transport of APP in
Alzheimer’s disease may be more closely linked to defects in
calsyntenin-1 rather than JIP1 mediated cargo transport.
MATERIALS AND METHODS
Plasmids and siRNAs
APP-EGFP was as described (9,59). Verified non-targeting
control and rat JIP1 siRNAs (#15 5′-CUGCUAUGCAAAA
GAUCGC-3′, #16 5′- CCAUGUUUUGGAGAUUACA-3′)
were purchased fromDharmacon (Accell range). Calsyntenin-1
pool siRNAs were as described (9) and also obtained from
Dharmacon.
Figure 3. siRNA knockdown of JIP1 does not effect axonal transport of APP-EGFP. (A) Representative kymographs showing axonal transport of APP-EGFP in
control and JIP1 siRNA-treated neurons. (B) and (C) show bar charts of APP-EGFP vesicle movement in control (Ctrl) and JIP1 siRNA treated neurons. (B)
shows APP-EGFP flux rates (as APP vesicles/minute) and (C) shows APP-EGFP velocities in both anterograde and retrograde directions. Statistical significance
was determined by Student’s t-test. n ¼ 26 control and 49 JIP1 siRNA treated cells. Error bars are SEM.
Table 1. Data for human post-mortem samples showing age at death, post-
mortem delay (PMD) and pathological diagnosis
Case Age (years) Sex PMD Pathological Diagnosis
A141/07 80 M 41 Alzheimer’s disease Braak VI
A065/04 91 F 29 Alzheimer’s disease Braak VI
A094/04 88 M 46 Alzheimer’s disease Braak VI
A059/07 92 F 42 Alzheimer’s disease Braak VI
A331/07 80 F 13 Alzheimer’s disease Braak V
A191/07 69 F 16 Alzheimer’s disease Braak VI
A210/05 84 F ,24 Alzheimer’s disease Braak V
A167/05 81 F ,72 Alzheimer’s disease Braak VI
A187/07 82 F 69 Alzheimer’s disease Braak V
A168/05 84 F 36 Alzheimer’s disease Braak V/VI
A247/05 90 F 23 Alzheimer’s disease Braak V/VI
A350/09 98 F 3.5 Alzheimer’s disease Braak V
A065/02 82 M 80 Alzheimer’s disease Braak V/VI
A318/09 72 M 5 Alzheimer’s disease Braak VI
A181/09 89 F 15 Alzheimer’s disease Braak V
A240/06 97 F 12 Alzheimer’s disease Braak V
A013/03 89 M 19 Alzheimer’s disease Braak V
A122/04 86 M 26 Alzheimer’s disease Braak V
A332/07 87 F 48 Alzheimer’s disease Braak VI
A140/07 81 F 17 Control
A153/06 92 F 17 Control
A134/00 86 M 6 Control
A358/08 55 F 12 Control
A192/09 80 M 21 Control
A063/10 90 F 50 Control
A239/03 78 M 10 Control
A265/08 79 M 47 Control
A040/07 82 F 13 Control
A124/04 59 M 50 Control
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Antibodies
Rabbit APP C-terminal and calsyntenin-1 antibodies were as
described (9,29,60,61). Mouse monoclonal antibodies to beta
actin (clone AC-15) were from Abcam (Cambridge, UK) and a
JIP-1 mouse monoclonal antibody (clone B-7) was from Santa
Cruz Biotechnology (Santa Cruz, USA). Anti-APP mouse clone
22C11 was from Merck Millipore (Billerica, USA); anti-sAPPa
clone 2B3 and anti-sAPPb rabbit polyclonal antibodies were
from IBL International (Hamburg, Germany), anti-phospho-
threonine-668 APP rabbit polyclonal antibody was fromCell Sig-
naling Technology (Danvers, USA). Anti NSE antibodywas from
Dako (Cambridge).
Cell culture and transfection
Cortical neurons were obtained from embryonic day 18 rat
embryos and cultured in Neurobasal medium containing B27
supplement, 100 IU/ml penicillin, 100 mg/ml streptomycin and
2 mM L-glutamine (Invitrogen). For siRNA studies, neurons at
DIV4 were treated with 1 mM of each siRNA (control, JIP1 or
calsyntenin-1) for 96 h and then analysed at DIV8. For transfec-
tion studies, neuronswere culturedonpoly-L-lysine-coated glass
cover slips in 12-well plates.Neuronswere transfected onamag-
netic plate for 30 minusing1 mgplasmidDNAand2 mlmagnet-
ic nanoparticles (NeuroMag, OZ Biosciences) as described by
the manufacturer. Neurons were transfected on DIV7 and ana-
lysed on DIV8.
Measurement of Ab production
To determine how loss of JIP1 affects production of endogenous
Ab(1–40) andAb(1–42), conditionedmedium from rat cortical
neurons at DIV4 cultured in 24-well plates (2.5 × 105 cells per
well) was removed and replaced with 400 ml fresh Neurobasal/
B27 medium containing 1 mM control, JIP1 or calsyntenin-1
siRNAs. The neurons were then returned to the incubator for a
further 96 h and the conditioned media then assayed for
Ab(1–40) and Ab(1–42). Some neurons were also treated
with 2 mM of the g-secretase inhibitor DAPT. For Ab assays,
the conditioned media was removed and centrifuged at
100000 × g for 30 min at 48C to remove any insoluble material.
Levels of Ab(1–40) and Ab(1–42) were then determined using
quantitative mouse/rat Ab ELISAs from Invitrogen (Ab(1–40)
ELISA KMB3481; Ab(1–42) ELISA KMB3441) according to
the manufacturer’s instructions. Data were analysed using
one-way ANOVA tests with Bonferroni post hoc test.
SDS–PAGE and immunoblotting
Cells were harvested for sodium dodecyl sulphate–polyacryl-
amide gel electrophoresis (SDS–PAGE) by washing with phos-
phate buffered saline pre-warmed at 378C and scraping into
SDS–PAGE sample buffer and immediately heating to 1008C.
Total sAPP, sAPPa and sAPPb levels in conditioned media
were likewise prepared for SDS–PAGE by addition of sample
buffer at heating to 1008C.
Humanbrain sampleswerepreparedas20%homogenates and
equal protein concentrations then prepared for SDS–PAGE by
addition of SDS–PAGE sample buffer and heating to 1008C.
Samples were separated on either 8 or 10% (w/v) acrylamide
gels; separatedproteinswere then transferred toProtrannitrocel-
lulose membranes (Schleicher & Schuell) using a Transblot
system (BioRad) and following blocking, probed with primary
antibodies. Following washing, the blots were further probed
withhorseradish peroxidase-conjugatedgoat anti-mouse or anti-
rabbit Igs and developed using an enhanced chemiluminescence
system (GE Healthcare).
Human tissues
All human tissue collection and processing were carried out
under the regulations and licensing of theHumanTissueAuthor-
ity and in accordance with the Human Tissue Act, 2004.
Figure 4. JIP1 levels are not altered in Alzheimer’s disease brains. (A) Immunoblots of representative samples from control and Alzheimer’s disease frontal cortex.
Samples were probed for JIP1 and NSE. (B–D) Bar charts showing relative levels (%) of JIP1 in the two sample sets following normalization to NSE signals in each
sample.Values shown are for total JIP1 (upper and lower species combined), upper JIP1 and lower JIP1 species.Datawere tested for normality using aKolmogorov–
Smirnov normality test, and differences between groups determined by aMann–Whitney test. n ¼ 10 control and n ¼ 19Alzheimer’s disease samples. Error bars are
SEM.
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Time-lapse microscopy
Livemicroscopy ofAPP-EGFPwas performedwith anAxiovert
S100 microscope (Zeiss) equipped with a Lambda LS Xenon-
Arc light source (Sutter Instrument Company, Novato, USA),
GFP filter set (Chroma Technology Corp., Rockingham,
USA), 100× Plan-Apochromat 1.4 N.A. objective (Zeiss),
Lambda 10–3 filter wheel (Sutter Instrument Co.) and a Photo-
metrics Cascade-II 512B High Speed EMCCD camera (Photo-
metrics, Tuscon, USA). Twenty-four hour post-transfection,
the cells were transferred to a Ludin imaging chamber (Life
Imaging Systems, Basel, Switzerland) mounted on the stage of
themicroscope. Neurons were maintained in a HEPES-buffered
extracellular neuronal solution (composition in mM: naCl, 140;
KCl, 5; NaHCO3, 5; MgCl2.6H20, 1; CaCl2, 1.2; Na2HPO4,
1.2; Glucose, 10; Hepes, 20; pH 7.4) at 378C using an objective
heater (IntraCell, Royston, UK) and ‘The Box’ Microscope
Temperature Control System (Life Imaging Systems). Vesicle
movements were recorded for 2 min with a 1 s time-lapse inter-
val usingMetaMorph software (MolecularDevices). Image ana-
lysis was performed with ImageJ. The flux rates for APP-EGFP
transport in both anterograde and retrograde directions were
determined essentially as described (8,9,46). This involved
quantifying the numbers of APP-EGFP particles that crossed a
defined line in mid-axons per minute. APP-EGFP velocities
were determined from kymographs, essentially as described
for other cargoes (62). Statistical significance was determined
by Student’s t-test.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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